Novo Nordisk A/S (NOVO-B) - Total Liabilities
Based on the latest financial reports, Novo Nordisk A/S (NOVO-B) has total liabilities worth Dkr348.86 Billion DKK (≈ $54.58 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novo Nordisk A/S - Total Liabilities Trend (1985–2025)
This chart illustrates how Novo Nordisk A/S's total liabilities have evolved over time, based on quarterly financial data. See NOVO-B net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Novo Nordisk A/S Competitors by Total Liabilities
The table below lists competitors of Novo Nordisk A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Industria de Diseno Textil SA
MC:ITX
|
Spain | €18.04 Billion |
|
BlackRock Inc
NYSE:BLK
|
USA | $106.92 Billion |
|
Charles Schwab Corp
NYSE:SCHW
|
USA | $765.00 Million |
|
Deere & Company
NYSE:DE
|
USA | $77.08 Billion |
|
Abbott Laboratories
NYSE:ABT
|
USA | $32.92 Billion |
|
Gilead Sciences Inc
NASDAQ:GILD
|
USA | $36.41 Billion |
|
Southern Copper Corporation
NYSE:SCCO
|
USA | $10.07 Billion |
|
AT&T Inc.
NYSE:T
|
USA | $293.57 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Novo Nordisk A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Novo Nordisk A/S (NOVO-B) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novo Nordisk A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novo Nordisk A/S (1985–2025)
The table below shows the annual total liabilities of Novo Nordisk A/S from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr348.86 Billion ≈ $54.58 Billion |
+8.24% |
| 2024-12-31 | Dkr322.31 Billion ≈ $50.43 Billion |
+55.01% |
| 2023-12-31 | Dkr207.93 Billion ≈ $32.53 Billion |
+31.79% |
| 2022-12-31 | Dkr157.77 Billion ≈ $24.68 Billion |
+27.48% |
| 2021-12-31 | Dkr123.76 Billion ≈ $19.36 Billion |
+51.67% |
| 2020-12-31 | Dkr81.60 Billion ≈ $12.77 Billion |
+19.96% |
| 2019-12-31 | Dkr68.02 Billion ≈ $10.64 Billion |
+15.42% |
| 2018-12-31 | Dkr58.93 Billion ≈ $9.22 Billion |
+12.16% |
| 2017-12-31 | Dkr52.54 Billion ≈ $8.22 Billion |
+0.52% |
| 2016-12-31 | Dkr52.27 Billion ≈ $8.18 Billion |
+16.60% |
| 2015-12-31 | Dkr44.83 Billion ≈ $7.01 Billion |
+21.93% |
| 2014-12-31 | Dkr36.77 Billion ≈ $5.75 Billion |
+32.41% |
| 2013-12-31 | Dkr27.77 Billion ≈ $4.34 Billion |
+10.91% |
| 2012-12-31 | Dkr25.04 Billion ≈ $3.92 Billion |
-8.12% |
| 2011-12-31 | Dkr27.25 Billion ≈ $4.26 Billion |
+11.51% |
| 2010-12-31 | Dkr24.44 Billion ≈ $3.82 Billion |
+28.56% |
| 2009-12-31 | Dkr19.01 Billion ≈ $2.97 Billion |
+7.58% |
| 2008-12-31 | Dkr17.67 Billion ≈ $2.76 Billion |
+13.46% |
| 2007-12-31 | Dkr15.57 Billion ≈ $2.44 Billion |
+6.90% |
| 2006-12-31 | Dkr14.57 Billion ≈ $2.28 Billion |
+1.84% |
| 2005-12-31 | Dkr14.30 Billion ≈ $2.24 Billion |
+29.93% |
| 2004-12-31 | Dkr11.01 Billion ≈ $1.72 Billion |
+19.73% |
| 2003-12-31 | Dkr9.19 Billion ≈ $1.44 Billion |
+7.45% |
| 2002-12-31 | Dkr8.56 Billion ≈ $1.34 Billion |
-2.17% |
| 2001-12-31 | Dkr8.75 Billion ≈ $1.37 Billion |
-1.23% |
| 2000-12-31 | Dkr8.86 Billion ≈ $1.39 Billion |
-28.66% |
| 1999-12-31 | Dkr12.41 Billion ≈ $1.94 Billion |
+33.41% |
| 1998-12-31 | Dkr9.30 Billion ≈ $1.46 Billion |
+23.86% |
| 1997-12-31 | Dkr7.51 Billion ≈ $1.18 Billion |
+49.54% |
| 1996-12-31 | Dkr5.02 Billion ≈ $785.94 Million |
-12.25% |
| 1995-12-31 | Dkr5.72 Billion ≈ $895.70 Million |
-28.41% |
| 1994-12-31 | Dkr8.00 Billion ≈ $1.25 Billion |
+9.76% |
| 1993-12-31 | Dkr7.29 Billion ≈ $1.14 Billion |
+17.14% |
| 1992-12-31 | Dkr6.22 Billion ≈ $973.13 Million |
+7.79% |
| 1991-12-31 | Dkr5.77 Billion ≈ $902.82 Million |
+5.47% |
| 1990-12-31 | Dkr5.47 Billion ≈ $855.98 Million |
+1.30% |
| 1989-12-31 | Dkr5.40 Billion ≈ $845.02 Million |
+45.96% |
| 1988-12-31 | Dkr3.70 Billion ≈ $578.93 Million |
+19.31% |
| 1987-12-31 | Dkr3.10 Billion ≈ $485.22 Million |
-23.91% |
| 1986-12-31 | Dkr4.08 Billion ≈ $637.69 Million |
+66.61% |
| 1985-12-31 | Dkr2.45 Billion ≈ $382.74 Million |
-- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more